New Stock News | Shenzhen Mindray Bio-Medical Electronics (300760.SZ) plans to conduct a Hong Kong IPO. The CSRC requires additional information on the use of funds raised in this offering.

On May 8, the China Securities Regulatory Commission announced the requirements for supplementary materials for overseas issuance and listing filing (April 27, 2026 - May 8, 2026). Among them, the CSRC requested Shenzhen Mindray Bio-Medical Electronics to explain whether the proceeds from this fundraising involve overseas investments, and whether relevant approval, approval, or filing procedures have been completed. According to the disclosure on November 10, 2025, by the Hong Kong Stock Exchange, Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (hereinafter referred to as Shenzhen Mindray Bio-Medical Electronics, 300760.SZ) submitted an application to the Hong Kong Stock Exchange Main Board, with Huatai International and J.P. Morgan acting as its joint sponsors. The CSRC requested Shenzhen Mindray Bio-Medical Electronics to provide clarification on the following matters and requested legal counsel to verify and provide clear legal opinions: 1. Please explain the development and operation of apps, mini-programs, WeChat official accounts, and other products by the company and its subsidiaries, and whether they involve the collection and use of personal information. If so, please provide information on the scale of information collected and stored, and the use of data. 2. Please explain whether the planned use of funds by the company involves overseas investments, and whether relevant approval, approval, or filing procedures have been completed. 3. The company and its subsidiaries' business scope includes "technology import and export." Please explain the status of relevant business operations and their compliance. 4. Please explain the specific compliance situation regarding the overseas investments and foreign exchange registration of the company's overseas subsidiaries, and provide conclusive opinions on their compliance. 5. Please explain whether the business scope and actual business operations of the company and its subsidiaries involve areas prohibited or restricted to foreign investment in the "Special Management Measures for Market Access of Foreign Investment (Negative List) (2024 Edition)." 6. Please explain the specific situation of the partial pledge of shares held by controlling shareholder Magnifice (HK), and its impact on the company's control and normal business operations. According to the prospectus, Shenzhen Mindray Bio-Medical Electronics is a globally leading, innovation-driven world-class medical device company and a leader in medical digitalization. According to Frost & Sullivan data, in the Chinese medical device industry, the company's market value in 2024 exceeded the sum of top domestic leaders (second to fifth place), and industrial revenue was more than twice that of the second place. The company has risen to 23rd place among the top global medical device companies, with rankings continuously improving, being the only Chinese company among the top 30 global medical device companies and one of the fastest-growing companies to join the list. The company adheres to a strategic layout and has formed a complete matrix covering multiple products and production lines. According to Frost & Sullivan data, the company is the only one among the top global medical device companies to cover multiple medical scenarios ranging from emergency rooms, operating rooms, intensive care units, general wards, to surgery, cardiology, laboratory, and ultrasound. According to Frost & Sullivan data, based on revenue in 2024, the company holds a leading position in several fields, with market shares in 6 product categories ranking in the top three globally and 9 product categories ranking first in China.